The Dramatic Rise and Financial Turbulence of BioNTech: A New Era of Ambitious Therapeutic Innovations
BioNTech is experiencing a transition with declining COVID-19 vaccine profits but has ambitious plans for innovative cancer therapies. Despite a drop to €1.08 per share, BioNTech exceeded market expectations, outperforming…